Literature DB >> 11322657

The c-Jun NH2-terminal kinase3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors.

S Yoshida1, K Fukino, H Harada, H Nagai, I Imoto, J Inazawa, H Takahashi, A Teramoto, M Emi.   

Abstract

By examining 19 human cell lines derived from brain tumors for altered expression of expressed sequence tags (ESTs) in chromosomal band 4q21-22, we detected loss of expression, in 10 cell lines, of two sequences, WI6336 and WI7913. Both corresponded to the c-Jun NH2-terminal kinase (JNK) 3. In the present study, genomic cloning revealed that the JNK3 gene consists of 14 exons interrupted by 13 introns; its transcription-initiation site is within exon 3 and the termination codon lies in exon 14. Fluorescence in situ hybridization (FISH) and radiation-hybrid mapping confirmed the gene to 4q21-22. Together with prior evidence that, in JNK3-deficient mice, the JNK3 signaling pathway mediates apoptosis in central nervous tissue, our results suggest that loss of expression of the JNK3 gene may play an important role in the development of brain tumors in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322657     DOI: 10.1007/s100380170086

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  16 in total

1.  Non-cell-autonomous induction of tissue overgrowth by JNK/Ras cooperation in a Drosophila tumor model.

Authors:  Mirka Uhlirova; Heinrich Jasper; Dirk Bohmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

Review 2.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

3.  Suppression of Ras-stimulated transformation by the JNK signal transduction pathway.

Authors:  Norman J Kennedy; Hayla K Sluss; Stephen N Jones; Dafna Bar-Sagi; Richard A Flavell; Roger J Davis
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

4.  Truncation of the CNS-expressed JNK3 in a patient with a severe developmental epileptic encephalopathy.

Authors:  Sarah A Shoichet; Laurence Duprez; Olivier Hagens; Vicki Waetzig; Corinna Menzel; Thomas Herdegen; Susann Schweiger; Bernard Dan; Esther Vamos; Hans-Hilger Ropers; Vera M Kalscheuer
Journal:  Hum Genet       Date:  2005-10-25       Impact factor: 4.132

Review 5.  Signal integration by JNK and p38 MAPK pathways in cancer development.

Authors:  Erwin F Wagner; Angel R Nebreda
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 6.  The functional contrariety of JNK.

Authors:  Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2007-08       Impact factor: 4.784

7.  JNK signalling modulates intestinal homeostasis and tumourigenesis in mice.

Authors:  Rocio Sancho; Abdolrahman S Nateri; Amaya Garcia de Vinuesa; Cristina Aguilera; Emma Nye; Bradley Spencer-Dene; Axel Behrens
Journal:  EMBO J       Date:  2009-06-11       Impact factor: 11.598

8.  Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.

Authors:  Hazel A Rogers; John-Paul Kilday; Cerys Mayne; Jennifer Ward; Martyna Adamowicz-Brice; Ed C Schwalbe; Steven C Clifford; Beth Coyle; Richard G Grundy
Journal:  Acta Neuropathol       Date:  2011-11-23       Impact factor: 17.088

9.  Disruption of Vps4 and JNK function in Drosophila causes tumour growth.

Authors:  Lina M Rodahl; Kaisa Haglund; Catherine Sem-Jacobsen; Franz Wendler; Jean-Paul Vincent; Karine Lindmo; Tor Erik Rusten; Harald Stenmark
Journal:  PLoS One       Date:  2009-02-04       Impact factor: 3.240

10.  The structural pathway of interleukin 1 (IL-1) initiated signaling reveals mechanisms of oncogenic mutations and SNPs in inflammation and cancer.

Authors:  Saliha Ece Acuner Ozbabacan; Attila Gursoy; Ruth Nussinov; Ozlem Keskin
Journal:  PLoS Comput Biol       Date:  2014-02-13       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.